NYSE:MBX MBX Biosciences (MBX) Stock Price, News & Analysis $9.17 -0.10 (-1.08%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$9.15 -0.02 (-0.16%) As of 04/25/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About MBX Biosciences Stock (NYSE:MBX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MBX Biosciences alerts:Sign Up Key Stats Today's Range$8.75▼$9.6450-Day Range$5.79▼$11.8352-Week Range$4.81▼$27.50Volume265,788 shsAverage Volume250,397 shsMarket Capitalization$306.50 millionP/E RatioN/ADividend YieldN/APrice Target$37.50Consensus RatingBuy Company OverviewMBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.Read More… MBX Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreMBX MarketRank™: MBX Biosciences scored higher than 43% of companies evaluated by MarketBeat, and ranked 706th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingMBX Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMBX Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about MBX Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for MBX Biosciences are expected to grow in the coming year, from ($13.25) to ($2.30) per share. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for MBX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMBX Biosciences does not currently pay a dividend.Dividend GrowthMBX Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for MBX. News and Social Media2.4 / 5News Sentiment0.36 News SentimentMBX Biosciences has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for MBX Biosciences this week, compared to 2 articles on an average week.Search Interest1 people have searched for MBX on MarketBeat in the last 30 days. MarketBeat Follows2 people have added MBX Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, MBX Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,600,619.00 in company stock and sold $0.00 in company stock.Read more about MBX Biosciences' insider trading history. Receive MBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MBX Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address MBX Stock News HeadlinesOra H. Pescovitz Buys 7,693 Shares of MBX Biosciences, Inc. (NYSE:MBX) StockApril 11, 2025 | insidertrades.comCompanies Like MBX Biosciences (NASDAQ:MBX) Are In A Position To Invest In GrowthApril 23 at 1:23 PM | finance.yahoo.com2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot-com bust, worse than the COVID crash, and even worse than the Great Depression. What's coming, he says, could soon crash the market by 50% or more – and keep it down for 10, 20, or even 30 years. April 26, 2025 | Stansberry Research (Ad)MBX Biosciences to Participate in Citizens and RBC May Investor ConferencesApril 22, 2025 | globenewswire.comAscendis Pharma initiated with an Outperform at RBC CapitalApril 16, 2025 | markets.businessinsider.comJMP Securities Initiates Coverage of MBX Biosciences (MBX) with Market Outperform RecommendationApril 11, 2025 | msn.comMBX Biosciences initiated with an Outperform at Citizens JMPApril 10, 2025 | markets.businessinsider.comMBX Biosciences adds biotech veteran to boardApril 9, 2025 | uk.investing.comSee More Headlines MBX Stock Analysis - Frequently Asked Questions How have MBX shares performed this year? MBX Biosciences' stock was trading at $18.43 at the beginning of the year. Since then, MBX stock has decreased by 50.2% and is now trading at $9.17. View the best growth stocks for 2025 here. How were MBX Biosciences' earnings last quarter? MBX Biosciences, Inc. (NYSE:MBX) posted its quarterly earnings data on Thursday, November, 7th. The company reported ($2.78) EPS for the quarter, missing the consensus estimate of ($2.72) by $0.06. When did MBX Biosciences IPO? MBX Biosciences (MBX) raised $163 million in an initial public offering on Friday, September 13th 2024. The company issued 10,200,000 shares at a price of $16.00 per share. When did MBX Biosciences' lock-up period expire? MBX Biosciences' lock-up period expired on Wednesday, March 12th. MBX Biosciences had issued 10,200,000 shares in its IPO on September 13th. The total size of the offering was $163,200,000 based on an initial share price of $16.00. Since the expiration of MBX Biosciences' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted. How do I buy shares of MBX Biosciences? Shares of MBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MBX Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that MBX Biosciences investors own include PepsiCo (PEP), Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN) and AstraZeneca (AZN). Company Calendar Last Earnings11/07/2024Today4/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:MBX Previous SymbolNYSE:MBX CIK1776111 Webmbxbio.com Phone(317) 659-0200FaxN/AEmployees36Year FoundedN/APrice Target and Rating Average Stock Price Target$37.50 High Stock Price Target$44.00 Low Stock Price Target$30.00 Potential Upside/Downside+308.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares33,424,000Free FloatN/AMarket Cap$306.50 million OptionableN/A BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NYSE:MBX) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MBX Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MBX Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.